Arbutus Biopharma CorpABUSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Whitefort Capital Management, LP | 7.90% | 13.2M | ▲ +1.90pp | 2024-02-14 |
| Whitefort Capital Master Fund, LP | 6.80% | 12.9M | flat | 2024-05-17 |
| BlackRock, Inc. | 6.20% | 10.4M | — | 2024-02-12 |
| Two Seas Capital LP | 5.40% | 9.0M | ▼ -0.30pp | 2024-02-14 |
| The Statement is filed on behalf of each of the following persons | 4.40% | 8.4M | — | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-02 | Lindsay Androski | President and CEO | Grant | 28.0K | $0.00 | $0 |
| 2026-02-02 | Tuan Nguyen | Chief Financial Officer | Grant | 73.5K | $0.00 | $0 |
1–2 of 2